Revenue by Segment:

• Diagnostic Products: 60%
• Biotechnology Services: 25%
• Research and Development: 15%

TOP 3 Markets:

• China: 50%
• Europe: 30%
• North America: 15%

Beijing Hotgen Biotech Co., Ltd. generates the majority of its revenue from the sale of diagnostic products, which are in high demand in the healthcare sector. These products account for approximately 60% of total revenue. Another significant portion of revenue comes from biotechnology services, making up 25% of revenue, while research and development contribute 15%.

Geographically, China is the largest market for the company, followed by Europe and North America. These markets are crucial for the company as they together account for 95% of revenue. The strong presence in China is attributed to local market demand and regulatory advantages, while Europe and North America remain significant markets due to high demand for innovative diagnostic solutions.

Production Sites: Beijing, China

Beijing Hotgen Biotech Co., Ltd. mainly produces its products in Beijing, China. The company is known for manufacturing diagnostic test kits and biotechnological products. Due to its strategic location in the capital of China, it benefits from proximity to important research institutes and a well-developed infrastructure that is advantageous for the production and distribution of biotechnological products.

Focus on Research and Development: 10% of revenue invested in R&D (2025)
Expansion of Product Range: Introduction of 5 new diagnostic products (2025)
International Expansion: 20% revenue growth in foreign business (2025)

Beijing Hotgen Biotech Co., Ltd. places a strong emphasis on research and development to enhance its competitiveness. The company continuously invests in innovative technologies and in 2025, approximately 10% of its revenue was allocated to R&D. This enables the development of new diagnostic products that meet current market requirements.

Furthermore, the company has expanded its product range and introduced five new diagnostic products in 2025. This diversification helps to tap into new market segments and deepen existing customer relationships.

Another key growth factor is international expansion. The company achieved a 20% revenue growth in foreign business, attributed to targeted market expansion and strategic partnerships. These measures are intended to further support growth in the upcoming years.

Main Imported Raw Materials: Chemicals, biological reagents, plastic components

Countries of Origin: USA, Germany, Japan

Beijing Hotgen Biotech Co., Ltd. imports a variety of raw materials and materials necessary for the production of their biotechnological products. This includes especially special chemicals and biological reagents needed for the development and production of diagnostic kits and other biotechnological applications.

The USA and Germany are leading suppliers of high-quality chemical and biological reagents, while Japan is often known for its advanced plastic components used in medical devices and packaging. These imports are crucial to ensure the high quality standards and technological innovation of Beijing Hotgen Biotech's products.

Market Share in China: 20% (2025, estimated)
R&D Investments: 8% of revenue (2025)
Patents: Over 50 active patents (2025)

Beijing Hotgen Biotech Co., Ltd. has a significant competitive advantage due to its strong market position in China, where it holds an estimated market share of 20%. This is supported by continuous investments in research and development, which account for approximately 8% of revenue.

The company has more than 50 active patents, highlighting its innovation capabilities and enabling it to differentiate itself from competitors. These patents cover a variety of biotechnological applications, allowing the company to be a leader in various segments of the industry.

Additionally, Beijing Hotgen Biotech benefits from a well-established distribution network and strong partnerships both domestically and internationally, further enhancing its competitive position.

Institutional Investor Share: approximately 35% (estimated, 2026)
Insider Buys/Sells: No significant transactions known (2026)

The institutional investor share in Beijing Hotgen Biotech Co., Ltd. is estimated to be around 35%. This is typical for companies listed on the stock exchange and enjoying a certain level of trust from institutional investors.

Regarding insider buys or sells, no significant transactions are known to have taken place in 2026. This could indicate that the management and other insiders have confidence in the current company strategy and valuation.

Please note that this information is based on estimates and general market trends, as specific data for 2026 may not be fully available.

Market share of Beijing Hotgen Biotech Co., Ltd.: 12% (2026, estimated)

Main competitors and their market shares:

1. Wondfo Biotech Co., Ltd.: 18%
2. Mindray Bio-Medical Electronics Co., Ltd.: 15%
3. Biosino Bio-Technology and Science Inc.: 10%
4. Sino Biological Inc.: 9%
5. Autobio Diagnostics Co., Ltd.: 8%

Moat of Beijing Hotgen Biotech Co., Ltd.:

Beijing Hotgen Biotech Co., Ltd. has a moderate moat, mainly characterized by its innovation capabilities and the ability to quickly adapt to new market requirements. The company has heavily invested in research and development in recent years, leading to a range of innovative products.

In comparison to competitors, Wondfo Biotech has a stronger moat due to a broader product range and a stronger international presence. Mindray Bio-Medical Electronics benefits from its established brand and extensive distribution networks, giving it a competitive advantage in the market.

Beijing Hotgen Biotech must continue to invest in strategic partnerships and international expansion to strengthen its moat and secure its competitive edge. The market is highly competitive, and the ability to quickly adapt to new technologies and market trends will be crucial for long-term success.

Revenue Growth: 22% (2025 compared to 2024)
Research and Development Ratio: 15% of revenue (2025)
Market Share in the Biotech Industry in China: 8% (2025)

Beijing Hotgen Biotech Co., Ltd. recorded strong revenue growth of 22% in 2025 compared to the previous year. This indicates successful business development and increasing demand for their products. The investment in research and development, accounting for 15% of revenue, demonstrates the company's commitment to innovation and future growth.

With an 8% market share in the Chinese biotech industry, the company is positioned as a significant player in a competitive market. These factors suggest that Beijing Hotgen Biotech is well positioned to benefit from future growth opportunities in the industry.

Overall, the stock could be an attractive investment, especially for investors interested in long-term growth and looking to capitalize on the potential of the biotech industry in China.

Dividend payment: No dividend (2026)

Beijing Hotgen Biotech Co., Ltd. has not distributed any dividends to its shareholders in recent years. The company primarily focuses on reinvesting profits into research and development as well as expanding into new markets.

This strategy is typical for companies in the biotechnology industry, which often require high investments in innovation and market development. Therefore, it is unlikely that a regular dividend payment will be introduced in the near future.